OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

Oxurion NV/  BE0003846632  /

Euronext - Brüssel
8/10/2022  5:35:05 PM Chg. +0.0060 Volume Bid5:40:00 PM Ask5:40:00 PM High Low
0.3200EUR +1.91% 39,328
Turnover: 12,520.5630		 0.3130Bid Size: 534 0.3200Ask Size: 3,424 0.3200 0.3150
GlobeNewswire 3/28 Oxurion to Participate in Needham Virtual Healthcare Conference
GlobeNewswire 3/25 Oxurion Publishes 2021 Annual Report
GlobeNewswire 3/17 Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Nova...
GlobeNewswire 3/7 Oxurion Successfully Closes EUR >10 Million in Private Placement
GlobeNewswire 3/3 OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US AND EUROPEAN HEALTHCARE INVESTORS IN A...
GlobeNewswire 3/3 OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US AND EUROPEAN HEALTHCARE INVESTORS IN A...
GlobeNewswire 2/22 Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEG...
GlobeNewswire 2/22 Oxurion NV announces 2021 Full Year Results and 2022 Outlook
GlobeNewswire 2/14 Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis...
GlobeNewswire 2/11 Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiog...
GlobeNewswire 2/8 Oxurion to Participate in the 2022 BIO CEO and Investor Conference
GlobeNewswire 1/18 OXURION to Participate in the 10th edition of Degroof Petercam’s Healthcare Conference
GlobeNewswire 1/7 Oxurion Provides Update on Clinical Pipeline Progress
GlobeNewswire 1/4 OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
GlobeNewswire 11/30/2021 Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEG...
GlobeNewswire 11/24/2021 OXURION to Present at the Ophthalmology Day at BTIG
GlobeNewswire 11/22/2021 OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventur...
GlobeNewswire 11/15/2021 OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrat...
GlobeNewswire 11/4/2021 Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommen...
GlobeNewswire 10/14/2021 AGTC Announces Two Key Leadership Team Appointments
GlobeNewswire 10/13/2021 Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment o...
GlobeNewswire 10/11/2021 OXURION - Positive Phase 2 Part A THR-149 data shared at the America Society of Retinal Specialists ...
GlobeNewswire 10/5/2021 Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
GlobeNewswire 10/5/2021 OXURION to Present at the Lytham Partners Fall 2021 Investor Conference
GlobeNewswire 9/30/2021 OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of ...